Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946580 · ClinicalTrials.gov registry record · Phase 4
Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 53
- Enrollment target
NCT02946580: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02946580 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02946580, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 53 participants
- Enrollment target
Study Summary
Constipation is a known complication of the postoperative period after spinal surgery, where prescription pain medicines called opioids are traditionally used in high doses for the treatment of surgery-related pain. The goal of this study is to determine the effectiveness of Movantik (naloxegol)-a FDA-approved drug used to treat constipation that is caused by opioids-in preventing constipation in patients undergoing spinal fusion surgery at MGH.
Interventions
- DRUG Sugar Pill
- DRUG MOVANTIK™ (naloxegol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02946580
The ClinicalTrials.gov registry entry for NCT02946580 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugar Pill is the first listed.
NCT02946580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02946580 about?
NCT02946580 is a clinical study titled "Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients". Constipation is a known complication of the postoperative period after spinal surgery, where prescription pain medicines called opioids are traditionally used in high doses for the treatment of surgery-related pain. The goal of this study is to determine the effectiveness of Movantik (naloxegol)-a F...
What is the current status of trial NCT02946580?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2017-01. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02946580?
The interventions under investigation include: Sugar Pill (DRUG), MOVANTIK™ (naloxegol) (DRUG).
Who is sponsoring clinical trial NCT02946580?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.